Dane Leone

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met its primary and secondary endpoints, which attracted investments from whales. Raymond...

The Phase 2 study of Ayala Pharmaceuticals Inc’s (NASDAQ: AYLA) AL101 candidate is scheduled to begin in the back half of this year. Although the first data from the study could come during 2021, a safety assessment of the first six patients may be available by the close of 2020, according to...

Sage Therapeutics Inc (NASDAQ: SAGE) shares fell more than 60% Thursday following a negative readout for its lead asset in major depressive disorder. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Overweight rating for Sage but lowered the price target from $217 to $125. (See...

Ocular Therapeutix Inc (NASDAQ: OCUL)'s failure to ace a late-stage study of its glaucoma treatment candidate has tempered Raymond James' optimism, although the firm is still bullish. The Analyst Dane Leone downgraded Ocular from Strong Buy to Outperform and reduced the price target from...

Bluebird bio, Inc, (NASDAQ: BLUE) has built a gene therapy platform with which the company genetically alters patient cells under laboratory conditions and then infusing the altered cells back into the patient in the form of a therapeutic product, according to Raymond James. The Analyst Raymond...

G1 Therapeutics Inc (NASDAQ: GTHX) reported positive top-line results Wednesday for its Phase 2 trilaciclib trial in small cell lung cancer. What Happened The candidate met primary endpoints in reducing the occurrence and duration of severe neutropenia. Compared to the placebo, it also allowed...

The FDA announced approval Monday of Loxo Oncology Inc (NASDAQ: LOXO) and Bayer AG (OTC: BAYRY) Vitrakvi — chemically larotrectinib — for adults and pediatric patients with advanced or metastatic solid tumors that have a neurotropic receptor tyrosine kinase, or...

Analysts at BTIG laid out the bullish case for owning shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) — a "storied" company with a strong growth outlook. BTIG's Dane Leone initiates coverage of Vertex's stock with a Buy and $200 price target, on the thesis that...

Just a day after Credit Suisse reinstated an Outperform rating on Johnson & Johnson (NYSE: JNJ) based on future gain from Actelion, BTIG and Atlantic Equities downgraded the stock from Neutral to Sell and Underweight, respectively, for nearly the opposite reason. Atlantic Equities: Weak Setup...

Shares of bluebird bio Inc (NASDAQ: BLUE) have gained 75 percent since the start of 2017, which prompted analysts at BTIG to downgrade the biotech company at the forefront of fighting against cancer. BTIG's Dane Leone downgrades Bluebird's stock rating from Buy to Neutral as many of the bullish...

Bluebird bio Inc (NASDAQ: BLUE), a clinical-stage biotechnology company that focuses on developing gene therapies for severe diseases and cancer, reported on Monday top-line results from a study called Starbeam. Starbeam explores the company's LentiD investigational gene therapy for the treatment...

As Juno Therapeutics Inc (NASDAQ: JUNO) continues to trail its peers, BTIG analyst Dane Leone sees the stock falling nearly 50 percent as he downgrades his rating to Sell and set a price target of $12 (see Dane Leone's track record). “The company is trailing peers [Kite Pharma Inc (NASDAQ:...

A solid strategy and great execution have led BTIG analyst, Dane Leone, to upgrade his recommendation on Kite Pharma Inc. (NASDAQ: KITE) to Buy, and set a price target of $100. The Core Theses That Sees Upside Over 20% Kita Pharma’s trademark brand, Aix-Cel, should garner approximately 60...

The ongoing Phase 2 studies of Regeneron Pharmaceuticals Inc’s (NASDAQ: REGN) nesvacumab could yield a favorable outcome, expanding the market opportunity for the company in wet Age-related Macular Degeneration [wet AMD] and Diabetic Macular Edema [DME], BTIG’s Dane Leone said in a...